Dermatology
Ingram JR, Wozniak MB, Passera A, Uhlmann L, Martinez AL, Bechara FG, Bender RH, McLeod LD, Martin S, Moreno SG, Marvel J, Ravichandran S, Kimball AB. The hidradenitis suppurativa symptom and impact diary: development and psychometric evaluation of a novel set of patient reported outcomes for hidradenitis suppurativa. Br J Dermatol. 2025 Nov 18;193(6):1155-64. doi: 10.1093/bjd/ljaf307
BACKGROUND: Hidradenitis suppurativa (HS) is associated with a substantial disease burden. Given the complex nature of HS-related symptoms, patient-reported outcome (PRO) measures are important to ensure that the patient experience is captured when evaluating the efficacy of treatments in clinical trials.
Ezzedine K, Soliman AM, DiBenedetti D, Greenblatt A, Julian EH, Patterson S, Rosmarin D. Meaningful Vitiligo Area Scoring Index (VASI) response thresholds based on qualitative interviews with adolescents. Poster presented at the European Academy of Dermatology and Venereology (EADV) Congress; September 17, 2025. Paris, France.
Abstract not available at this time.
Rosmarin D, Soliman A, DiBenedetti D, Greenblatt A, Sen R, Patterson S, Ezzedine K. Qualitative development of items to assess noticeability and sun sensitivity for patients with non-segmental vitiligo. Poster presented at the European Academy of Dermatology and Venereology (EADV) Congress; September 17, 2025. Paris, France.
Ezzedine K, Soliman AM, DiBenedetti D, Greenblatt A, Patterson S, Rosmarin D. Is EQ-5D-5L suitable for assessing health-related quality of life among patients with nonsegmental vitiligo? Insights from qualitative patient interviews. Poster presented at the European Academy of Dermatology and Venereology (EADV) Congress; September 17, 2025. Paris, France.
Cha-Silva AS, Zhang KH, Graham C, Kurosky SK, Tran H, Law EH, Song EJ. A cost per responder analysis of ritlecitinib and baricitinib: assessing the impact of clinical efficacy and dosing variability on overall treatment costs of severe Alopecia Areata (AA). Poster presented at the ISPOR 2025; May 15, 2025. Montréal, Canada.
OBJECTIVE: To develop a cost-per-responder (CPR) analysis for ritlecitinib and baricitinib for the treatment of severe AA to address uncertainties in budget impact of these new therapies resulting from differences in clinical efficacy and available dosages.
Blauvelt A, Reckleff J, Zhao Y, Clark M, Kosa K, Harris N, Esfandiari E, Martin S, Whalley D, Emma GY. Content evaluation of pruritus, skin pain and sleep disturbance patient-reported outcome measures for adolescents and adults with moderate-to-severe atopic dermatitis: qualitative interviews. Br J Dermatol. 2024 Oct 4. doi: 10.1093/bjd/ljae346
Kohli RK, Hawe E, Harold S, Simou E, Chrysos AE, Orfanos P. Utility scores in chronic spontaneous urticaria: a systematic literature review and statistical analysis. Poster presented at the European Academy of Dermatology & Venereology (EADV) Congress 2024; September 25, 2024. Amsterdam, Netherlands.
INTRODUCTION AND OBJECTIVES: Chronic spontaneous urticaria (CSU) has a substantial impact on patient health-related quality of life (HRQoL). This study aims to document published utility values associated with CSU health states and derive new CSU health-state utility scores using recent randomized clinical trial (RCT) data.
Bhutani T, Jayade S, Rege S, Penton H, Patel V, Kalirai S, Wolin D, Boyle K, Seigel L. Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey. J Dermatolog Trea. 2024 Jun 24;35(1):2366532. doi: 10.1080/09546634.2024.2366532
PURPOSE: This noninterventional, cross-sectional survey estimated the prevalence and consequences of residual disease in apremilast-treated US adults with moderate to severe psoriasis.